Literature DB >> 16926399

Vaccinations with recombinant variants of Aspergillus fumigatus allergen Asp f 3 protect mice against invasive aspergillosis.

James I Ito1, Joseph M Lyons, Teresa B Hong, Daniel Tamae, Yi-Kuang Liu, Sharon P Wilczynski, Markus Kalkum.   

Abstract

A vaccine that effectively protects immunocompromised patients against invasive aspergillosis is a novel approach to a universally fatal disease. Here we present a rationale for selection and in vivo testing of potential protein vaccine candidates, based on the modification of an immunodominant fungal allergen for which we demonstrate immunoprotective properties. Pulmonary exposure to viable Aspergillus fumigatus conidia as well as vaccination with crude hyphal extracts protects corticosteroid-immunosuppressed mice against invasive aspergillosis (J. I. Ito and J. M. Lyons, J. Infect. Dis. 186:869-871, 2002). Sera from the latter animals contain antibodies with numerous and diverse antigen specificities, whereas sera from conidium-exposed mice contain antibodies predominantly against allergen Asp f 3 (and some against Asp f 1), as identified by mass spectrometry. Subcutaneous immunization with recombinant Asp f 3 (rAsp f 3) but not with Asp f 1 was protective. The lungs of Asp f 3-vaccinated survivors were free of hyphae and showed only a patchy low-density infiltrate of mononuclear cells. In contrast, the nonimmunized animals died with invasive hyphal elements and a compact peribronchial infiltrate of predominantly polymorphonuclear leukocytes. Three truncated versions of rAsp f 3, spanning amino acid residues 15 to 168 [rAsp f 3(15-168)], 1 to 142, and 15 to 142 and lacking the known bipartite sequence required for IgE binding, were also shown to be protective. Remarkably, vaccination with either rAsp f 3(1-142) or rAsp f 3(15-168) drastically diminished the production of antigen-specific antibodies compared to vaccination with the full-length rAsp f 3(1-168) or the double-truncated rAsp f 3(15-142) version. Our findings point to a possible mechanism in which Asp f 3 vaccination induces a cellular immune response that upon infection results in the activation of lymphocytes that in turn enhances and/or restores the function of corticosteroid-suppressed macrophages to clear fungal elements in the lungs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16926399      PMCID: PMC1594836          DOI: 10.1128/IAI.00815-06

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  45 in total

1.  Rapid identification of allergen-encoding cDNA clones by phage display and high-density arrays.

Authors:  Rimantas Kodzius; Claudio Rhyner; Zoltan Konthur; Donald Buczek; Hans Lehrach; Gerald Walter; Reto Crameri
Journal:  Comb Chem High Throughput Screen       Date:  2003-03       Impact factor: 1.339

2.  Detection of secreted peptides by using hypothesis-driven multistage mass spectrometry.

Authors:  Markus Kalkum; Gholson J Lyon; Brian T Chait
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-18       Impact factor: 11.205

3.  Reverse vaccinology and genomics.

Authors:  Rino Rappuoli; Antonello Covacci
Journal:  Science       Date:  2003-10-24       Impact factor: 47.728

4.  Invasive pulmonary aspergillosis in patients with hematologic malignancies: survival and prognostic factors.

Authors:  Maricel Subirà; Rodrigo Martino; Tomás Franquet; Carmen Puzo; Albert Altés; Ana Sureda; Salut Brunet; Jorge Sierra
Journal:  Haematologica       Date:  2002-05       Impact factor: 9.941

5.  Regulation by granulocyte-macrophage colony-stimulating factor and/or steroids given in vivo of proinflammatory cytokine and chemokine production by bronchoalveolar macrophages in response to Aspergillus conidia.

Authors:  Elmer Brummer; Marika Kamberi; David A Stevens
Journal:  J Infect Dis       Date:  2003-02-07       Impact factor: 5.226

6.  Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.

Authors:  Raoul Herbrecht; David W Denning; Thomas F Patterson; John E Bennett; Reginald E Greene; Jörg-W Oestmann; Winfried V Kern; Kieren A Marr; Patricia Ribaud; Olivier Lortholary; Richard Sylvester; Robert H Rubin; John R Wingard; Paul Stark; Christine Durand; Denis Caillot; Eckhard Thiel; Pranatharthi H Chandrasekar; Michael R Hodges; Haran T Schlamm; Peter F Troke; Ben de Pauw
Journal:  N Engl J Med       Date:  2002-08-08       Impact factor: 91.245

7.  A role for antibodies in the generation of memory antifungal immunity.

Authors:  Claudia Montagnoli; Silvia Bozza; Angela Bacci; Roberta Gaziano; Paolo Mosci; Joachim Morschhäuser; Lucia Pitzurra; Manfred Kopf; Jim Cutler; Luigina Romani
Journal:  Eur J Immunol       Date:  2003-05       Impact factor: 5.532

8.  Vaccination of mice against invasive aspergillosis with recombinant Aspergillus proteins and CpG oligodeoxynucleotides as adjuvants.

Authors:  Silvia Bozza; Roberta Gaziano; Grayson B Lipford; Claudia Montagnoli; Angela Bacci; Paolo Di Francesco; Viswanath P Kurup; Hermann Wagner; Luigina Romani
Journal:  Microbes Infect       Date:  2002-11       Impact factor: 2.700

Review 9.  New antifungal agents.

Authors:  Aditya K Gupta; Elizabeth Tomas
Journal:  Dermatol Clin       Date:  2003-07       Impact factor: 3.478

10.  Vaccination of corticosteroid immunosuppressed mice against invasive pulmonary aspergillosis.

Authors:  James I Ito; Joseph M Lyons
Journal:  J Infect Dis       Date:  2002-08-20       Impact factor: 5.226

View more
  33 in total

Review 1.  Enzymatic Mechanisms Involved in Evasion of Fungi to the Oxidative Stress: Focus on Scedosporium apiospermum.

Authors:  C Staerck; P Vandeputte; A Gastebois; A Calenda; S Giraud; N Papon; J P Bouchara; M J J Fleury
Journal:  Mycopathologia       Date:  2017-06-21       Impact factor: 2.574

Review 2.  Antibody-mediated protection through cross-reactivity introduces a fungal heresy into immunological dogma.

Authors:  Arturo Casadevall; Liise-anne Pirofski
Journal:  Infect Immun       Date:  2007-08-20       Impact factor: 3.441

3.  Proteomic studies in biomedically and industrially relevant fungi.

Authors:  Stephen Carberry; Sean Doyle
Journal:  Cytotechnology       Date:  2007-02-17       Impact factor: 2.058

Review 4.  Aspergillus vaccines: Hardly worth studying or worthy of hard study?

Authors:  Stuart M Levitz
Journal:  Med Mycol       Date:  2016-09-17       Impact factor: 4.076

Review 5.  Immunotherapy for opportunistic infections: Current status and future perspectives.

Authors:  Shigeo Fuji; Jürgen Löffler; Hermann Einsele; Markus Kapp
Journal:  Virulence       Date:  2016-07-06       Impact factor: 5.882

Review 6.  Proteomics as a Tool to Identify New Targets Against Aspergillus and Scedosporium in the Context of Cystic Fibrosis.

Authors:  Andoni Ramirez-Garcia; Aize Pellon; Idoia Buldain; Aitziber Antoran; Aitana Arbizu-Delgado; Xabier Guruceaga; Aitor Rementeria; Fernando L Hernando
Journal:  Mycopathologia       Date:  2017-05-08       Impact factor: 2.574

7.  Hypothermic endpoint for an intranasal invasive pulmonary aspergillosis mouse model.

Authors:  Trinka W Adamson; Diana Diaz-Arevalo; Tracey M Gonzalez; Xueli Liu; Markus Kalkum
Journal:  Comp Med       Date:  2013       Impact factor: 0.982

Review 8.  Vaccine immunity against fungal infections.

Authors:  Som G Nanjappa; Bruce S Klein
Journal:  Curr Opin Immunol       Date:  2014-03-03       Impact factor: 7.486

9.  Healthy human T-Cell Responses to Aspergillus fumigatus antigens.

Authors:  Neelkamal Chaudhary; Janet F Staab; Kieren A Marr
Journal:  PLoS One       Date:  2010-02-17       Impact factor: 3.240

10.  Aspergillus fumigatus stimulates the NLRP3 inflammasome through a pathway requiring ROS production and the Syk tyrosine kinase.

Authors:  Najwane Saïd-Sadier; Eduardo Padilla; Gordon Langsley; David M Ojcius
Journal:  PLoS One       Date:  2010-04-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.